All In MedTech

Device Trial Radar · NCT03091712

Insulin Degludec Titration Using Mobile Insulin Dosing System

Last checked: Nov 20, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

May 5, 2017

Primary completion

Aug 8, 2019

Study completion Sep 15, 2019

Sponsor

Lead sponsor
GlookoNot on our public-company list
Sponsor type
Industry
First posted
Mar 27, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label randomized, controlled, parallel intervention study. Group 1 will receive usual care for insulin degludec titration using the STEP WISE degludec titration algorithm Group 2 will receive Glooko mobile insulin dosing system, using the STEP WISE degludec titration algorithm.An estimated n= 240 subjects with type 2 diabetes will be enrolled in order to obtain approximately 200 evaluable subjects who will complete the 16 week study.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Glooko Mobile Insulin Dosing System(MIDS)Device

    Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scripps Whittier Diabetes Institute

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.